🧾 Schedule III On A White House Clock

Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.

Today’s edition tracks a White House-driven Schedule III push and the institutional aftershocks that arrive before any rule changes, from banking posture to marketing limits and hemp’s scramble for a federal standards lane.

Today’s edition is supported by Superhuman AI and The Hustle Daily. If you want your work in front of the same decision-makers, reach out to learn how to become a sponsor!

🏛️ Schedule III timing and leverage
🏦 Banking reality check
🥤 Hemp standards endgame

Clarity beats adrenaline.

📌 What Happened: President Trump is weighing a White House directive that would push marijuana toward Schedule III, with reporting pointing to a Wednesday or Thursday window for a possible announcement. The Wall Street Journal framed the moment as a contrast in governing style: Biden set the process in motion through an HHS review that produced a Schedule III recommendation, then the effort drifted without a finish. Reuters describes the current posture as an attempt to accelerate reclassification and widen the research lane, while also warning that timing and sequencing remain unsettled. The practical question is less about whether the words “Schedule III” get said and more about whether the administration commits to the slow, document-heavy work that makes a change durable. Until there is text, though, this remains more smoke than fire.

💡 Why It Matters: Cannabis has spent a decade living in America’s favorite kind of arrangement: tolerated in practice, unresolved on paper. A White House push toward Schedule III does not settle that contradiction, but it forces powerful institutions to revisit the assumptions they have used to stay on the sidelines. Once the possibility feels immediate, risk committees convene, outside counsel gets looped in, and the industry gets handed new questionnaires, new covenants, and new representations to sign. The 280E piece is why this heats up so fast, because tax treatment shows up as cash, and cash shows up in valuations, debt service, and whether a lender decides to keep talking. A more direct approach also invites process fights, which makes counterparties cautious even when they want to be constructive. Operators end up carrying the weight of other people’s uncertainty, and that is where bad terms get accepted and sloppy statements get memorialized.

🧒 Kids Online Safety Act Moves With Cannabis Ad Limits

House Energy and Commerce’s CMT subcommittee advanced the Kids Online Safety Act after adding a direct instruction for covered platforms: do not facilitate advertising of “cannabis products” to users the platform knows are minors. The “knowledge” standard includes willful disregard, which pushes platforms to treat youth exposure risk as their problem to solve. That usually means broader automated blocks, tighter ad review, and more takedowns of borderline content, even when brands are trying to reach verified adults in legal states. Operators should assume higher friction in paid social and build redundancy through first-party lists, owned channels, and cleaner age-gating workflows. (Marijuana Moment)

🥤 Hemp Scrambles For A Federal Standards Off-Ramp Before The Ban Hits

After Congress tucked an intoxicating-hemp ban into last month’s shutdown-ending bill, hemp beverage and edible makers are shifting toward federal regulation instead of betting everything on repeal. Rep. Nancy Mace has a repeal bill, but Sen. Rand Paul’s effort to strip the provision already failed 76–24, and he is now floating a narrower bridge that protects states with existing rules while Congress builds a national framework. Sens. Ron Wyden and Jeff Merkley’s Cannabinoid Safety and Regulation Act sketches that framework with serving and package limits, FDA oversight for testing, labeling, recalls, and marketing limits aimed at youth appeal, plus prevention and impaired-driving grant programs. Minnesota sits at the center of the argument: an age-gated, low-dose model lawmakers point to for jobs and tax revenue, caught in the blast radius of federal language aimed at the worst actors. The remaining question is legislative vehicle and timing, and the January 31 funding deadline is the obvious lever. (MinnPost)

🏦 Senators Warn Banking Pain Persists Even If DEA Reschedules

Senate Banking’s financial institutions subcommittee used a hearing on state regulatory experience to underline the industry’s most stubborn problem: cash. Sen. Catherine Cortez Masto said rescheduling would not solve cannabis banking access and pushed Congress to move a SAFER-style fix. Chair Thom Tillis agreed the gap needs attention but signaled he wants tighter guardrails around youth appeal and marketing. Former Nevada regulator Tyler Klimas described how banking friction bleeds into oversight, forcing states and licensees into workarounds that reduce transparency and raise public-safety risk. The hearing left one clear takeaway: safe harbor lives in statute, and Congress is the only body that can deliver it at scale. (Marijuana Moment)

🗳️ Senate Advances Trump’s Drug Czar Nominee

Senate Majority Leader John Thune filed cloture to move Sara Carter Bailey’s nomination to lead the Office of National Drug Control Policy toward a floor vote. The nomination has been stuck in a procedural holding pattern after an earlier attempt to fast-track it ran into objections. DEA still controls scheduling mechanics, and ONDCP shapes how an administration frames enforcement, prevention, and research across agencies. With rescheduling chatter already moving markets and counterparties, leadership at ONDCP becomes a posture tell. Treat the vote as an institutional marker, then wait for written scheduling action before treating anything as settled. (Cannabis Business Times)

🧑‍🏭 New Jersey Senate Moves To Extend Union Rights And ULP Protections To Cannabis Workers

New Jersey lawmakers are advancing a bill that would expand state-backed organizing, bargaining, and unfair labor practice protections for cannabis workers where federal coverage can be unclear in parts of the industry. The measure would empower the State Board of Mediation to investigate and remedy unfair practices, including reinstatement, back pay, and damages tied to retaliation or interference with organizing. It also raises the pressure on employers with potential penalties of up to $5,000 per day for noncompliance. For operators, this is HR risk with a regulator’s teeth, especially around discipline, terminations, and supervisor conduct during organizing drives. The bill cleared Senate Judiciary and moved to Senate Budget and Appropriations, where enforcement design and fiscal assumptions start to matter. (Shore News Network)

📉 Connecticut Adult-Use Prices Keep Sliding, Still Double Massachusetts

Connecticut’s average adult-use flower price fell again in November to $7.94 per gram, down from $8.43 in October, extending a decline that has been in place since February. Massachusetts averaged $4.01 per gram in November, leaving Connecticut at roughly double the price even as both markets continue to grind lower. Connecticut’s retail sales softened to about 592,300 products and roughly $18.4 million in November, down slightly from October, and medical sales declined as well. Massachusetts posted a seasonal dip too, from about $141.6 million in October to $135.2 million in November. The gap keeps pressure on Connecticut operators who built around higher prices and now need scale, differentiation, or both. (Inside Investigator)

💸 Boston’s First Rec Dispensary Sued Over $63K Supplier Tab

Blue Fox Brands Massachusetts, Inc. sued Pure Oasis, LLC in Suffolk Superior Court on December 4th, alleging Pure Oasis owes $63,429.81 for cannabis products ordered and received between March and May. Pure Oasis co-owner Kobie Evans said the company is dealing with heavier competition and lower prices and described the balance as one they can address while discussions continue. The dispute lands as more Massachusetts retailers surrendered licenses in FY25 than any prior year, a reminder that stress shows up first as ordinary credit conflict. Evans also said the company expected support from the Cannabis Social Equity Trust Fund and did not receive it, which strained finances during a Brighton buildout. Pure Oasis says the Brighton location remains on track for a first-quarter 2026 opening and is central to its recovery plan. (Boston Business Journal)

💼 Jushi Reworks CEO Compensation To Preserve Cash

Jushi Holdings amended CEO Jim Cacioppo’s employment agreement as the company manages near-term working capital needs. A $1.05 million cash bonus that otherwise would have been paid by March 15, 2026, plus options tied to 3 million subordinate voting shares, was restructured into a $300,000 lump-sum payment and 3 million restricted subordinate voting shares that vest on January 1, 2026 if he remains employed. The company said independent directors approved the change and disclosed it as a related-party transaction under MI 61-101 while relying on exemptions tied to size relative to market capitalization. This is a public-company tell about runway management, with equity doing the retention work that cash cannot. (Cannabis Business Times)

💊 Vertanical Lines Up A 2026 EU Launch For VER-01 Back Pain Drug

Vertanical says it plans to release its VER-01 chronic low back pain medicine in Europe in 2026 after publishing results from two randomized controlled trials totaling more than 1,300 patients. The company describes the product as a standardized, whole-plant, full-spectrum oral extract marketed as Exilby, and says German authorization plus the EU mutual recognition pathway could broaden access across Europe. If the results translate into real-world prescribing, this is the kind of “pharma-shaped” cannabis medicine that clinicians and payors know how to evaluate and adopt. That matters less for state programs directly and more for legitimacy in health-system rooms that have treated cannabis as noise. (Business of Cannabis)

🍺➡️🌿 Managed Alcohol Program Adds Cannabis, Drinking Drops

A Canadian managed alcohol program began offering participants a choice in January 2023: take the scheduled alcohol dose or take a pre-rolled cannabis joint. Program records showed mean daily program-provided alcohol falling from 8.08 to 6.45 standard drinks after cannabis was added as an option. Researchers also reported an association over the study period consistent with substitution for some participants, even as day-to-day patterns did not move in lockstep. The policy relevance is practical harm reduction: defined units, legal supply, and a supervised setting where outcomes can be tracked instead of argued about. It is a useful counterweight to a debate that often treats cannabinoids only as a youth-risk headline. (StratCann)